logo

Progenics Pharmaceuticals Inc (PGNX)



Trade PGNX now with
  Date
  Headline
8/7/2018 11:00:17 PM Progenics Pharma Prices Underwritten Public Offering Of 9.09 Mln Shares At $8.25/shr
6/26/2018 8:37:15 AM Progenics Completes Enrollment Of Phase 2/3 Trial Of PSMA-Targeted PET/CT Imaging Agent PyL In Prostate Cancer
6/8/2018 7:00:35 AM Amicus Therapeutics Appoints President And COO Bradley Campbell To Board
6/4/2018 8:39:28 AM Progenics Announces Presentation Of Updated Data From Pivotal Trial Of AZEDRA
5/9/2018 7:55:03 AM Progenics Pharma Q1 Net Loss $13.4 Mln Or $0.19/Shr Vs Loss Of $16.4 Mln Or $0.23/Shr Last Year
3/19/2018 8:33:52 AM Progenics Pharma Announces Presentation Of AZEDRA Biochemical Tumor Marker Data
3/8/2018 7:50:03 AM Progenics Pharmaceuticals Q4 Revenue $3.9 Mln, Net Loss Attributable $2.7 Mln Or $0.04 Per Share
12/29/2017 8:32:47 AM Progenics Announces FDA Acceptance Of NDA For AZEDRA In Pheochromocytoma And Paraganglioma
11/2/2017 8:13:15 AM Progenics Pharma Q3 Net Loss $15.4 Mln Or $0.22/shr Vs. Net Income $36.3 Mln Or $0.52/shr Last Year